"We are pleased to enter this strategic collaboration with PharmaEssentia," Jingsong Wang, M.D., PhD, Chairman of Nona Biosciences, said, " PharmaEssentia's therapeutic solutions reflect its motivation for reshaping the treatment path for progressive cancers, and we believe that by leveraging Nona's antibody discovery ability, we can accelerate the R&D process of novel therapies."

"We are delighted to partner with Nona Biosciences as we continue to expand our research capabilities and technical expertise at our newly established PIRC," said Lih-Ling Lin PhD, Chief Scientific Officer of PharmaEssentia "We look forward to growing our footprint in the Boston area as we assemble our team of scientists and complete the build-out of our new lab space this year."